Figure 2.

NTD (N) sequence between AF1 and ID is required for JDP-2 potentiation of the partial agonist activity of RU486. A, Schematic illustration of PR-B internal deletion constructs. B, COS-1 cells were transfected with PRE₂-TATA-Luc (200 ng) together with varying doses of wild-type or deletion PR-B constructs expressed from pCDNA1 (1–12.5 ng). Cells were treated with vehicle or R5020 (10 nm) for the final 24 h of transfection. C, COS-1 cells were transfected with PRE₂-TATA-Luc (200 ng) together with a single dose of phPR-B expressing wild-type PR-B, Δ323 PR-B, or Δ475 PR-B (1.5 ng each) in the presence or absence of pCR3.1-JDP-2 (100 ng). Cells were treated for the final 24 h of transfection with vehicle, or 10 nm R5020 or RU486, as indicated. Fold luciferase induction by ligands and fold enhancement by JDP-2 were calculated as in Fig. 1. Values are averages ± sem of at least three independent experiments. WT, Wild type.